[HTML][HTML] Progress in epidermolysis bullosa research: toward treatment and cure
Journal of Investigative Dermatology, 2010•Elsevier
Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of blistering
disorders with considerable morbidity and mortality. Two decades ago, EB entered the
molecular era with the identification of mutations in specific genes expressed within the
cutaneous basement membrane zone; mutations in 14 genes have now been identified.
This progress has now formed the basis for development of novel molecular therapies for
this disease.
disorders with considerable morbidity and mortality. Two decades ago, EB entered the
molecular era with the identification of mutations in specific genes expressed within the
cutaneous basement membrane zone; mutations in 14 genes have now been identified.
This progress has now formed the basis for development of novel molecular therapies for
this disease.
Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of blistering disorders with considerable morbidity and mortality. Two decades ago, EB entered the molecular era with the identification of mutations in specific genes expressed within the cutaneous basement membrane zone; mutations in 14 genes have now been identified. This progress has now formed the basis for development of novel molecular therapies for this disease.
Elsevier